Letter: Cancer Paradox and Short-term STEMI-related Outcomes

Abstract

Get full access to this article

View all access options for this article.

References

Chia

Ang

Usman

Krittanawong

Mukherjee

Trends, characteristics and outcomes in breast cancer survivors with STEMI. Angiology. 2026;77:375-84.

Okşul

Şener

Sarıkaya

, et al. Breast artery calcification as an opportunistic predictor of cardiovascular disease. Ir J Med Sci. 2023;192:625-31.

Abdel-Qadir

Bobrowski

Zhou

, et al. Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc. 2021;10:e018393.

Shugg

Nguyen

Hua

, et al. Factors associated with the recovery of left ventricular ejection fraction in patients with anthracycline-induced left ventricular dysfunction. J Cardiovasc Pharmacol Ther. 2025;30:10742484241304304.

Labib

Haykowsky

Sonnex

, et al. Long-term cardiac MRI follow up of MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology REsearch). Cardiooncology. 2025;11:13.

Neilan

Quinaglia

Onoue

, et al. Atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA. 2023;330:528-36.

Bonatto

Ferreira

Avila

, et al. Effects of sacubitril-valsartan on prevention of cardiotoxicity in high-risk patients undergoing anthracycline chemotherapy: a double-blind randomized placebo-controlled clinical trial – the SARAH trial. Circulation. 2024;150:e724-5.

Lyon

López-Fernández

Couch

, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229-361.

Meattini

Curigliano

Terziani

, et al. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. Med Oncol. 2017;34:75.

10.

Khosrow-Khavar

Filion

Al-Qurashi

, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol. 2017;28:487-96.

11.

Zheng

Risk of cardiovascular disease in breast cancer patients receiving aromatase inhibitors vs. tamoxifen: a systematic review and meta-analysis. J Clin Pharm Ther. 2022;47:575-87.

12.

Rygiel

Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: insights from recent clinical trials. Indian J Pharmacol. 2016;48:490.

13.

Yandrapalli

Malik

Pemmasani

, et al. Risk factors and outcomes during a first acute myocardial infarction in breast cancer survivors compared with females without breast cancer. Am J Med. 2020;133:444-51.

14.

Madias

JE.

Right versus left breast radiation and coronary artery disease: is there a differential?

Acta Cardiol. 2023;78:5-12.

15.

Carlson

Watt

Tonorezos

, et al. Coronary artery disease in young women after radiation therapy for breast cancer: the WECARE study. JACC CardioOncol. 2021;3:381-92.

16.

Milo

MLH

Thorsen

LBJ

Johnsen

, et al. Risk of coronary artery disease after adjuvant radiotherapy in 29,662 early breast cancer patients: a population-based Danish Breast Cancer Group study. Radiother Oncol. 2021;157:106-13.